Femoxetine is a selective serotonin re-uptake inhibitor. It was being studied in the treatment of narcolepsy, migraine, depressive states and eating disorder. Femoxetine development has been discontinued.

Dibupyrone is an analgesic agent.

Lofendazam is partial benzodiazepine agonist. It has been widely tested as a psychotherapeutic drug. In particular, as an anxiety treatment agent.

Davasaicin is a synthetic derivative of capsaicin, developed at the Korea Research Institute of Chemical Technology. Davasaicin possesses very potent analgesic activity, demonstrated in several animal models, such as phenylbenzoquinone-induced writhing test, tail-flick test in mice and adjuvant arthritic flexion test in rats. When administered topically, davasaicin has an antipruritic effect in the mouse model.

Clonazoline is an imidazoline sympathomimetic, an alpha-adrenoreceptor agonist. It was used as a nasal decongestant and vasoconstrictor. The drug was marketed in Italy in combination with Fluocinolone under tradename Localyn.

Otenabant (CP-945,598) is Pfizer developed as a potent and selective cannabinoid receptor CB1 antagonist with Ki of 0.7 nM, which exhibits 10,000-fold greater selectivity against human CB2 receptor, for treatment of obesity. In clinical trial III Pfizer decided to discontinue the development program based on changing regulatory perspectives on the risk/benefit profile of the CB1 class and likely new regulatory requirements for approval.

Tianafac (also known as L8109) is a thienylacetic acid derivative patented by Labaz group as antipyretics and anti-inflammatory agent useful for the treatment of arthritis. In preclinical models, Tianafac inhibits prostaglandin formation by seminal vesicle microsomes and exerts antipyretic, analgetic, and moderate gastric ulcerogenic activity and had a wide safety margin between toxic and pharmacologically active doses.

Carbubarb is hydroxyalkylmalonylurea derivatives patented by pharmaceutical company Consortium Mondial des Grandes Marques as sedatives and hypnotic agent.

Talmetacin is a cyclo-oxygenase inhibitor that was studied as an analgesic and antipyretic agent. This drug was studied in Argentina in patients with rheumatic disorders. However, further development of talmetacin is not available.

Prizidilol (also known as SKF 92657) is arylpyridazinylhydrazine derivative patented by Smith Kline and French Laboratories Ltd. as an antihypertensive agent. In clinical trials, Supine and standing blood pressure measured 24--27 h after drug intake was reduced Slight but significant decreases in heart rate were seen after moderate doses of prizidilol. A more pronounced blood pressure reduction was noticed 2--7 h after drug administration. Prizidilol was well tolerated, although dizziness and tiredness were reported by four patients and edema by two.